The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
In patients with contralateral occlusion, carotid endarterectomy (CEA) yields equivalent outcomes compared with carotid artery stenting (CAS), according to new data presented June 9, 2012, at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback